TNFSF13 and breast carcinoma: These and other, not yet identified, effects of APRIL/BCMA, together with the reported toxicity, cytokine release syndrome and neurological toxicity, after the application of anti-BCMA therapies in hematologic malignancies, discussed above, suggest that extreme caution should be exercised before initiating relevant clinical studies in breast cancer.